# KLOW peptide references: the cited research record

> KLOW peptide references — the full cited literature behind every claim on this site, with DOIs and PubMed links for each of the four components and the 2024-2026 studies.

Every quantitative claim on this site maps to a numbered source below. Component-level studies and the 2024-2026 record, with DOIs and PubMed links.

## How to read this list

Every source below is component-level — a study of KPV, GHK-Cu, BPC-157 or thymosin beta-4 on its own — because no controlled study of the four-peptide KLOW blend exists. The numbers match the inline citation markers used across this site's [recent KLOW research](/research), [KLOW side effects](/side-effects) and [reported KLOW effects](/effects) pages. Where a claim is attributed to the blend rather than a single arm, the text says so explicitly and points to this absence.

## References

[1] Malinda KM, Sidhu GS, Mani H, Banaudha K, Maheshwari RK, Goldstein AL, Kleinman HK. Thymosin beta4 accelerates wound healing. J Invest Dermatol. 1999;113(3):364-368. https://pubmed.ncbi.nlm.nih.gov/10469335/
[2] Staresinic M, Sebecic B, Patrlj L, et al. Gastric pentadecapeptide BPC 157 accelerates healing of transected rat Achilles tendon and in vitro stimulates tendocytes growth. J Orthop Res. 2003;21(6):976-983. https://pubmed.ncbi.nlm.nih.gov/14554208/
[3] Dalmasso G, Charrier-Hisamuddin L, Nguyen HT, Yan Y, Sitaraman S, Merlin D. PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation. Gastroenterology. 2008;134(1):166-178. https://pubmed.ncbi.nlm.nih.gov/18061177/
[4] Pickart L, Vasquez-Soltero JM, Margolina A. GHK Peptide as a Natural Modulator of Multiple Cellular Pathways in Skin Regeneration. BioMed Research International. 2015;2015:648108. https://pmc.ncbi.nlm.nih.gov/articles/PMC4508379/
[5] Pickart L, Margolina A. Regenerative and Protective Actions of the GHK-Cu Peptide in the Light of the New Gene Data. International Journal of Molecular Sciences. 2018;19(7):1987. https://pmc.ncbi.nlm.nih.gov/articles/PMC6073405/
[6] Lee S, Lee SM, Lee SH, Choi WK, Park SJ, Kim DY, et al. In situ photo-crosslinkable hyaluronic acid-based hydrogel embedded with GHK peptide nanofibers for bioactive wound healing. Acta Biomaterialia. 2023. https://pubmed.ncbi.nlm.nih.gov/37832839/
[7] Dymek M, Olechowska K, Hac-Wydro K, Sikora E. Liposomes as Carriers of GHK-Cu Tripeptide for Cosmetic Application. Pharmaceutics. 2023;15(10):2485. https://pmc.ncbi.nlm.nih.gov/articles/PMC10610410/
[8] Lee E, Burgess K. Safety of Intravenous Infusion of BPC157 in Humans: A Pilot Study. Altern Ther Health Med. 2025. https://pubmed.ncbi.nlm.nih.gov/40131143/
[9] Mendias CL, Awan TM. Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance. Sports Med. 2026. https://pubmed.ncbi.nlm.nih.gov/41966639/
[10] Sun Q, et al. PepT1-targeted nanodrug based on co-assembly of anti-inflammatory peptide and immunosuppressant for combination treatment of acute and chronic DSS-induced colitis. Front Pharmacol. 2024;15:1442876. https://pubmed.ncbi.nlm.nih.gov/39211778/
[11] Mortazavi SM, Mohammadi Vadoud SA, Moghimi HR. Topically applied GHK as an anti-wrinkle peptide: Advantages, problems and prospective. BioImpacts. 2025. https://pmc.ncbi.nlm.nih.gov/articles/PMC11830136/
[12] World Anti-Doping Agency. The Prohibited List — S2, Peptide Hormones, Growth Factors, Related Substances and Mimetics (thymosin beta-4 / TB-500 prohibited at all times). WADA. https://www.wada-ama.org/en/prohibited-list
[13] Mao S, Huang J, Li J, Sun F, Zhang Q, Cheng Q, Zeng W, Lei D, Wang S, Yao J. Exploring the beneficial effects of GHK-Cu on an experimental model of colitis and the underlying mechanisms. Frontiers in Pharmacology. 2025. https://pmc.ncbi.nlm.nih.gov/articles/PMC12263609/
[14] Regeneration or Risk? A Narrative Review of BPC-157 for Musculoskeletal Healing. Curr Rev Musculoskelet Med. 2025. https://pubmed.ncbi.nlm.nih.gov/40789979/
[15] Tracheocutaneous Fistula Resolved by Pentadecapeptide BPC 157 Therapy Through the NO-System. Pharmaceuticals (Basel). 2026;19(1):145. https://pubmed.ncbi.nlm.nih.gov/41599743/

---

A plain-language field guide that maps the KLOW research to its sources and marks honestly where the road runs out — not a clinic, not a vendor, not a prescription.